JP2023552274A - 抗ウイルス化合物としての重水素化アミノチアゾール化合物 - Google Patents

抗ウイルス化合物としての重水素化アミノチアゾール化合物 Download PDF

Info

Publication number
JP2023552274A
JP2023552274A JP2023526237A JP2023526237A JP2023552274A JP 2023552274 A JP2023552274 A JP 2023552274A JP 2023526237 A JP2023526237 A JP 2023526237A JP 2023526237 A JP2023526237 A JP 2023526237A JP 2023552274 A JP2023552274 A JP 2023552274A
Authority
JP
Japan
Prior art keywords
alkyl
deuterium
compound according
fluoro
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552274A5 (enExample
Inventor
ゲゲ、クリスチャン
クレイマン、ジェラルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovative Molecules GmbH
Original Assignee
Innovative Molecules GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules GmbH filed Critical Innovative Molecules GmbH
Publication of JP2023552274A publication Critical patent/JP2023552274A/ja
Publication of JP2023552274A5 publication Critical patent/JP2023552274A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2023526237A 2020-10-29 2021-10-28 抗ウイルス化合物としての重水素化アミノチアゾール化合物 Pending JP2023552274A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20204545.6 2020-10-29
EP20204545 2020-10-29
PCT/EP2021/080023 WO2022090409A1 (en) 2020-10-29 2021-10-28 Deuterated aminothiazole compounds as antiviral compounds

Publications (2)

Publication Number Publication Date
JP2023552274A true JP2023552274A (ja) 2023-12-15
JP2023552274A5 JP2023552274A5 (enExample) 2024-10-22

Family

ID=73037895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526237A Pending JP2023552274A (ja) 2020-10-29 2021-10-28 抗ウイルス化合物としての重水素化アミノチアゾール化合物

Country Status (9)

Country Link
US (1) US12552756B2 (enExample)
EP (1) EP4237414A1 (enExample)
JP (1) JP2023552274A (enExample)
KR (1) KR20230131177A (enExample)
CN (1) CN116783171A (enExample)
AU (1) AU2021367976A1 (enExample)
CA (1) CA3196645A1 (enExample)
MX (1) MX2023004955A (enExample)
WO (1) WO2022090409A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4466255A1 (en) 2022-01-17 2024-11-27 Innovative Molecules GmbH Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
WO2026078039A1 (en) 2024-10-09 2026-04-16 Innovative Molecules Gmbh Oral administration forms of antiviral helicase-primase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519134A (ja) * 1999-12-23 2003-06-17 バイエル アクチェンゲゼルシャフト チアゾリルアミド誘導体
WO2019068817A1 (en) * 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
JP2019515883A (ja) * 2016-04-06 2019-06-13 イノベーティブ モレキュールズ ゲーエムベーハーＩｎｎｏｖａｔｉｖｅ Ｍｏｌｅｃｕｌｅｓ Ｇｍｂｈ 抗ウイルス剤として有用なアミノチアゾール誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519134A (ja) * 1999-12-23 2003-06-17 バイエル アクチェンゲゼルシャフト チアゾリルアミド誘導体
JP2019515883A (ja) * 2016-04-06 2019-06-13 イノベーティブ モレキュールズ ゲーエムベーハーＩｎｎｏｖａｔｉｖｅ Ｍｏｌｅｃｕｌｅｓ Ｇｍｂｈ 抗ウイルス剤として有用なアミノチアゾール誘導体
WO2019068817A1 (en) * 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOSTER, A. B.: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, vol. 14, JPN6021009664, 1985, pages 1 - 40, ISSN: 0005804879 *
O'DRISCOLL: "Heavyweight drugs", CHEMISTRY & INDUSTRY, JPN6021009665, 9 March 2009 (2009-03-09), pages 24 - 26, ISSN: 0005804881 *
PIRALI, TRACEY ET AL.: "Applications of deuterium in medicinal chemistry", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62(11), JPN7025003766, 2019, pages 5276 - 5297, ISSN: 0005804880 *

Also Published As

Publication number Publication date
CN116783171A (zh) 2023-09-19
AU2021367976A9 (en) 2025-03-13
EP4237414A1 (en) 2023-09-06
KR20230131177A (ko) 2023-09-12
US20230391738A1 (en) 2023-12-07
MX2023004955A (es) 2023-05-17
WO2022090409A1 (en) 2022-05-05
US12552756B2 (en) 2026-02-17
AU2021367976A1 (en) 2023-06-08
CA3196645A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
EP3692039B1 (en) Enantiomers of substituted thiazoles as antiviral compounds
JP2023552274A (ja) 抗ウイルス化合物としての重水素化アミノチアゾール化合物
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
JP2025502300A (ja) ヘリカーゼプリマーゼ阻害剤の固体結晶形態及びその製造方法
CA3244921A1 (en) USE OF AN HPK1 INHIBITOR IN THE TREATMENT OF INTERFERON-RELATED DISEASES
CN110483487B (zh) 一种2-硫甲基吡唑嘧啶酮类化合物、其制备方法、药物组合物及应用
US20160368944A1 (en) Linked purine pterin hppk inhibitors useful as antibacterial agents
JP7773233B2 (ja) Ｐｅｔ放射性トレーサとしての［１８ｆ］標識イミダゾピリジン誘導体
CN118556045A (zh) 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法
HK40110051A (zh) 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法
HK40090317A (zh) 作为pet放射性示踪剂的[18f]-标记的咪唑幷吡啶衍生物
TW201920144A (zh) 環丁基-咪唑啶酮化合物
HK1235064A1 (en) Indole carboxamides compounds useful as kinase inhibitors
HK1235064B (en) Indole carboxamides compounds useful as kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260226